LBF20000PG01: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=13,14-dihydro PGE1 is an inhibitor of ADP-induced platelet aggregation in human PRP. | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 06:00, 7 January 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1707 |
| LipidMaps | LMFA03010144 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20000PG01 |
| 13,14-dihydro Prostaglandin E1 | |
|---|---|
| |
| Structural Information | |
| 9-oxo-11α,15S-dihydroxy-prostan-1-oic acid | |
| |
| Formula | C20H36O5 |
| Exact Mass | 356.256274262 |
| Average Mass | 356.49684 |
| SMILES | C(CC[C@@H](O)CC[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC |
| Physicochemical Information | |
| 13,14-dihydro PGE1 is an inhibitor of ADP-induced platelet aggregation in human PRP. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
